Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Hello, and welcome to Regeneron Pharmaceuticals' fourth quarter 2024 earnings conference call. My name is Tawanda, and I will be your operator for today's call. (Operator Instructions) Please note ...

Johnson & Johnson (NYSE: JNJ) has gone big early doors this year in the world of pharma M&A. The US healthcare giant ...

Regeneron (NASDAQ:REGN) Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship ...

Regeneron (NASDAQ:REGN) Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex landscape of challenges and opportunities in ...

Regeneron pledged $119.5m while Illumina is ... interplay between genetics and health in unprecedented detail.” The UK Biobank, which holds genetic and health information from 500,000 ...

Regeneron invested $119.5 million in Truveta’s Series C funding ... Truveta touts the endeavor as being more than 10 times the scale of other health care databases, such as the UK Biobank, which ...

On the basis of its industry-leading capabilities, Regeneron Genetics Center was selected by UK BioBank consortium members to complete proteomic assay data generation for the recently announced UK ...

Regeneron will sequence the genomes ... the U.S. National Institutes of Health's All of Us Research Program and the UK Biobank. Those databases represent 850,000 and 500,000 participants ...

The new investment — which comes from 17 health systems, Illumina, and Regeneron — pushes Truveta ... including NIH’s All of Us and the UK Biobank, according to the startup.

Regeneron co-Chair, President and CSO George ... in an Air Fryer How Donald Trump’s trade tariffs could affect the UK ...